Latest Breaking News On - Lixte biotechnology holdings inc - Page 11 : comparemela.com

Home / Top News / Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24 Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24 More than 40 preclinical studies have found that Lixte’s lead drug candidate LB-100 increases the anti-tumor activity of chemotherapy, radiotherapy and immunotherapy without increasing toxicity EAST SETAUKET, NY, March 17, 2021 (GLOBE NEWSWIRE) Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the virtual Benzinga Biotech Small Cap Conference being held March 24-25, 2021. Lixte Founder and Chief Executive Officer John S. Kovach, M.D., will present on Wednesday, March 24 at 10:55 a.m. ET in Track 1. Investors may register for the conference at t

United statesJohns kovachExchange commissionSecurities exchangeLixte biotechnology holdings incBiotechnology holdingsBenzinga biotech small cap conferenceLixte founderChief executive officer johnLixte biotechnology holdingsSecurities actSecurities exchange actUnited states securitiesஒன்றுபட்டது மாநிலங்களில்ஜான்ஸ் கோவாச்பரிமாற்றம் தரகு